Anti-Fumonisin [2A2]
Anti-Fumonisin [2A2]
Product No.: 90015
- -
- -
Clone 2A2 Target Fumonisin Formats AvailableView All Product Type Monoclonal Isotype IgG1 Applications ELISA |
- -
- -
Antibody DetailsProduct DetailsReactivity Species Fusarium Host Species Mouse Immunogen Fumonisin-BSA conjugate. Formulation Lyophilized, 0.1M Tris, 0.1M glycine, 2% sucrose, 1mg/ml. State of Matter Lyophilized Product Preparation Purified by Protein A affinity chromatography Storage and Handling This product is stable for at least one (1) year at -20°C to -70°C. Reconstituted product should be stored in appropriate aliquots to avoid repeated freeze-thaw cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco ELISA: use at 0.1-0.5ug/ml.
These are recommended concentrations. End user should determine optimal concentrations for their applications. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Mouse Monoclonal Antibody specific to Fumonisin Background The fumonisins are a group of myco- toxins produced primarily by Fusarium verticillioides and Fusarium proliferatum. Maize is the most commonly contaminated crop. Fusarium verticillioides and fumonisins are found worldwide. The primary health concerns associated with fumonisins are acute toxic effects in horses and swine and carcinogenic properties. Fumonisins are carcinogenic to laboratory animals, and, in humans, consumption of fumonisin- contaminated maize is associated with higher rates of esophageal cancer and neural tube birth defects. Fumonisins were first characterized in the late 1980s, as a result of studies into the causes of esophageal cancer in Africa, coupled with outbreaks of equine leuko- encephalomalacia and porcine pulmonary edema in the U.S. Antigen DetailsResearch Area Agriculture/Food Science References & CitationsTechnical Protocols |
Formats Available
